Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Iteos Therapeutics Inc.
Headquarters: Watertown, MA, United States of America
Website: http://www.iteostherapeutics...
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Michel Detheux, PhD
Number Of Employees: 173
Enterprise Value: $-178,708,723
PE Ratio: -1.63
Exchange/Ticker 1: NASDAQ:ITOS
Exchange/Ticker 2: N/A
Latest Market Cap: $217,707,504
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Sep 26, 2024
Product Development
ESMO recap: Keeping TIGIT alive, Rybrevant & immunotherapy anniversary — a BioCentury podcast
Plus: Special guest Gwyn Bebb of Parexel on his conference takeaways, COVID vaccines for cancer and radiopharma
BioCentury | Sep 18, 2024
Product Development
View from ESMO: iTeos data keep TIGIT alive, for now
Plus readouts from Genmab, AstraZeneca, Merck, Astellas and more
BioCentury | Sep 14, 2024
Management Tracks
Egle names Detheux chairman
Plus: BeiGene adds to commercial leadership, hiring Pfizer veteran Matt Shaulis, and updates from Wells Fargo, Flagship, Alume, Cytek, Aetion and 180 Life Sciences
BioCentury | Aug 7, 2024
Management Tracks
Flagship adds White House veteran Panjabi
Plus: Biogen alum Radhakrishnan joins Sofinnova Investments, and updates from Bicycle, iTeos, Fennec, Faron and ORIC
BioCentury | May 10, 2024
Finance
Public equity report: iTeos, ADC Therapeutics, Eledon draw fundings
Biotechs all gave clinical updates during busy earnings week
BioCentury | Jan 5, 2024
Management Tracks
Friedman succeeding Hoos at Scorpion
Plus: 4DMT hires Noriyuki Kasahara as CSO, and updates from SV, Omega, AbbVie Ventures, Nikang, Immunome, Wugen, Zevra and Quris
BioCentury | Dec 7, 2023
Product Development
The first-in-human immuno-oncology problem
Companies face growing challenges in deciding whether to advance an immuno-oncology program based on early Phase I data
BioCentury | Aug 24, 2023
Product Development
As TIGIT optimism surges, commercial prospects become the question
Leaked interim OS data from Roche’s tiragolumab renew confidence in the TIGIT program
BioCentury | Dec 19, 2022
Product Development
Arcus’ TIGIT data don’t provide hoped for differentiation
Domvanalimab/PD-1 combo doesn’t stack up to Roche combo, which missed Phase III endpoint
Items per page:
1 - 10 of 40